S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The 3-Stock Retirement Blueprint (Ad)
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
NYSE:EBS

Emergent BioSolutions - EBS Stock Forecast, Price & News

$20.99
+0.21 (+1.01%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$20.89
$21.88
50-Day Range
$20.09
$35.80
52-Week Range
$20.06
$55.35
Volume
519,483 shs
Average Volume
604,045 shs
Market Capitalization
$1.05 billion
P/E Ratio
12.42
Dividend Yield
N/A
Price Target
$48.83

Emergent BioSolutions MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
132.7% Upside
$48.83 Price Target
Short Interest
Bearish
5.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.50mentions of Emergent BioSolutions in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.63) to $1.76 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

165th out of 1,093 stocks

Pharmaceutical Preparations Industry

62nd out of 547 stocks

EBS stock logo

About Emergent BioSolutions (NYSE:EBS) Stock

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Stock News Headlines

Emergent BioSolutions (NYSE:EBS) Shares Gap Up to $20.53
The 3-Stock Retirement Blueprint
When most folks think about making money through the markets, they think “buy and hold.” They think “diversification.” And they think about investing in things like index funds. But one man has a different approach… It’s called the “3-Stock Retirement Blueprint.”
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast
He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January… And now, he’s issuing a brand-new warning – along with a unique solution.
See More Headlines
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Company Calendar

Last Earnings
8/01/2022
Today
10/01/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
CUSIP
29089Q10
Employees
2,416
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.83
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+132.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$230.90 million
Pretax Margin
8.45%

Debt

Sales & Book Value

Annual Sales
$1.79 billion
Cash Flow
$8.53 per share
Book Value
$30.09 per share

Miscellaneous

Free Float
44,327,000
Market Cap
$1.05 billion
Optionable
Optionable
Beta
1.07

Key Executives

  • Mr. Robert G. Kramer Sr. (Age 65)
    CEO, Pres & Exec. Director
    Comp: $1.93M
  • Mr. Richard S. LindahlMr. Richard S. Lindahl (Age 58)
    Exec. VP, CFO & Treasurer
    Comp: $858.61k
  • Mr. Adam R. Havey (Age 51)
    Exec. VP & COO
    Comp: $843.1k
  • Mr. Atul Saran (Age 49)
    Exec. VP & Chief Strategy and Devel. Officer
    Comp: $820.66k
  • Mr. Robert G. Burrows
    VP of Investor Relations
  • Ms. Jennifer L. Fox
    Exec. VP of External Affairs, Gen. Counsel & Corp. Sec.
  • Ms. Coleen Glessner
    Exec. VP of Global Quality and Ethics & Compliance
  • Ms. Lynn Kieffer
    VP of Corp. Communications
  • Ms. Katherine Strei (Age 60)
    Exec. VP of HR & Chief HR Officer













EBS Stock - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings
or view top-rated stocks.

What is Emergent BioSolutions' stock price forecast for 2022?

6 brokerages have issued 1 year price targets for Emergent BioSolutions' shares. Their EBS share price forecasts range from $29.00 to $77.00. On average, they anticipate the company's stock price to reach $48.83 in the next year. This suggests a possible upside of 132.7% from the stock's current price.
View analysts price targets for EBS
or view top-rated stocks among Wall Street analysts.

How have EBS shares performed in 2022?

Emergent BioSolutions' stock was trading at $43.47 at the beginning of 2022. Since then, EBS shares have decreased by 51.7% and is now trading at $20.99.
View the best growth stocks for 2022 here
.

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 1,950,000 shares, a decrease of 34.8% from the August 15th total of 2,990,000 shares. Based on an average daily trading volume, of 619,300 shares, the days-to-cover ratio is currently 3.1 days. Approximately 4.8% of the shares of the company are short sold.
View Emergent BioSolutions' Short Interest
.

When is Emergent BioSolutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our EBS earnings forecast
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) released its earnings results on Monday, August, 1st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.63 by $1.49. The biopharmaceutical company had revenue of $242.70 million for the quarter, compared to analysts' expectations of $268.77 million. Emergent BioSolutions had a trailing twelve-month return on equity of 12.22% and a net margin of 6.02%. The company's revenue for the quarter was down 38.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.33 earnings per share.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions issued an update on its third quarter 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $230.00 million-$270.00 million, compared to the consensus revenue estimate of $301.17 million.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $20.99.

How much money does Emergent BioSolutions make?

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $1.05 billion and generates $1.79 billion in revenue each year. The biopharmaceutical company earns $230.90 million in net income (profit) each year or $1.69 on an earnings per share basis.

How many employees does Emergent BioSolutions have?

The company employs 2,416 workers across the globe.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.

This page (NYSE:EBS) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.